Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.72 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.72 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.133 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.133 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.133 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.133 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.5.1 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.5.1 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.5.1 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.5.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.43.7 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.43.7 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.43.7 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.43.7 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.33.1 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.33.1 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.33.1 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.33.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
XDENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
XDENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
XDNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.493ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.493ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.493ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.493NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.351.2 (Beta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.351.2 (Beta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.351.2 (Beta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.351.2 (Beta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.640.2ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.640.2ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.640.2ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.640.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.352ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.1.352ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.1.352ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.1.352NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.251ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.1.251ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.1.251ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.1.251NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HC.1ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
HC.1ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
HC.1ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
HC.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCJORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
XCJENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
XCJENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
XCJNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used